Varian, a Siemens Healthineers company, has obtained FDA clearance for its TrueBeam and Edge radiotherapy systems featuring the innovative HyperSight imaging solution. This advancement aims to enhance treatment accuracy and minimize damage to healthy tissues during radiation therapy. HyperSight allows for high-quality imaging during treatment sessions, facilitating precise targeting of tumor volumes. With faster acquisition times and reduced patient discomfort, HyperSight is poised to improve the overall patient experience. Varian remains committed to advancing radiotherapy through collaborative research and innovation, ushering in a new era of personalized cancer care.
Varian, now a part of Siemens Healthineers, has recently achieved a significant milestone with the reception of FDA 510(k) clearance for its TrueBeam and Edge radiotherapy systems, both featuring the cutting-edge HyperSight imaging solution. This clearance underscores Varian’s commitment to advancing the field of radiotherapy by introducing innovative technologies aimed at enhancing treatment accuracy and ultimately improving patient outcomes.
HyperSight is a revolutionary imaging solution designed to elevate the precision of radiotherapy treatments while prioritizing the protection of healthy tissues. With its integration into the TrueBeam and Edge systems, Varian continues to push the boundaries of imaging capabilities within the radiotherapy treatment room, introducing new functionalities and workflows across its range of linear accelerators.
At the heart of HyperSight is its ability to provide clinicians with high-quality images throughout a patient’s daily radiation treatment regimen. These enhanced images enable clinicians to more accurately target tumor volumes while minimizing damage to surrounding healthy tissue. By delivering Hounsfield Unit (HU) accurate images directly on acquired cone-beam CT (CBCT) scans, HyperSight facilitates offline adaptive planning, allowing for adjustments to treatment plans based on anatomical changes without the need for additional scans on a separate CT scanner.
One of the standout features of HyperSight on TrueBeam and Edge systems is its ability to acquire images for all anatomical sites at a significantly faster rate, with a 50% faster gantry rotation compared to traditional CBCT scans. This reduction in acquisition time not only enhances efficiency but also minimizes motion-related artifacts caused by patient movement. Additionally, the shorter imaging time contributes to a more comfortable and less anxiety-inducing experience for patients undergoing radiation therapy.
The Cancer Institute at Northwell Lenox Hill in New York was among the first institutions to adopt HyperSight imaging on their Halcyon system. Dr. Wesley Talcott, Assistant Professor and Radiation Oncologist at Lenox Hill Hospital, noted the positive impact of HyperSight on patient comfort and treatment accuracy. The technology has enabled them to decrease the time patients spend on the treatment table while simultaneously improving targeting precision, ultimately enhancing the overall patient experience.
Since its initial launch on Varian’s Ethos and Halcyon therapy systems in 2022, HyperSight has garnered significant interest from clinicians and researchers alike. With nine studies either underway or planned across eight institutions, Varian remains dedicated to exploring the potential of HyperSight in advancing patient care and elevating the standard of radiotherapy. The Intelligent Imaging Consortium, initiated by Varian, serves as a collaborative platform for HyperSight users to engage in trials and studies, further fostering innovation in the field.
Arthur Kaindl, Head of Varian, expressed excitement about expanding HyperSight imaging technology to the TrueBeam and Edge platforms. He emphasized Varian’s commitment to pioneering innovative solutions that not only advance radiotherapy but also seamlessly integrate imaging capabilities throughout the cancer care continuum. As part of Siemens Healthineers, Varian continues to lead the way in revolutionizing radiotherapy and enhancing patient care through groundbreaking technologies like HyperSight.
The FDA clearance for Varian’s TrueBeam and Edge radiotherapy systems featuring HyperSight imaging technology marks a significant step forward in the field of cancer treatment. By enabling clinicians to obtain high-quality images with increased speed and accuracy, HyperSight enhances the precision of radiation therapy while minimizing the impact on healthy tissues. This advancement not only improves treatment outcomes but also enhances the overall patient experience by reducing discomfort and anxiety during treatment sessions. As Varian continues to innovate and collaborate with clinical partners, HyperSight promises to play a pivotal role in advancing personalized cancer care and improving the lives of patients worldwide.
